Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
202.4 SEK | +78.17% | +72.11% | +59.24% |
Sales 2024 * | 1.88B 178M | Sales 2025 * | 3.21B 304M | Capitalization | 10.86B 1.03B |
---|---|---|---|---|---|
Net income 2024 * | -39M -3.69M | Net income 2025 * | 1.09B 104M | EV / Sales 2024 * | 5.7 x |
Net cash position 2024 * | 125M 11.85M | Net cash position 2025 * | 1.21B 114M | EV / Sales 2025 * | 3.01 x |
P/E ratio 2024 * |
36.3
x | P/E ratio 2025 * |
8.77
x | Employees | 217 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.29% |
Latest transcript on Calliditas Therapeutics AB
1 day | +78.17% | ||
1 week | +72.11% | ||
Current month | +84.00% | ||
1 month | +95.18% | ||
3 months | +81.52% | ||
6 months | +112.38% | ||
Current year | +59.24% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 17-05-17 | |
Director of Finance/CFO | 47 | 17-07-31 | |
Chief Tech/Sci/R&D Officer | 60 | 20-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 23-05-29 |
Henrik Stenqvist
BRD | Director/Board Member | 57 | 21-12-31 |
Elmar Schnee
CHM | Chairman | 65 | 19-05-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - | |
0.00% | 1 M€ | 0.00% | - | |
0.00% | 29 M€ | -2.30% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 202.4 | +78.17% | 7,863,576 |
24-05-27 | 113.6 | -0.79% | 244,141 |
24-05-24 | 114.5 | -6.30% | 634,133 |
24-05-23 | 122.2 | +7.19% | 1,675,625 |
24-05-22 | 114 | -1.72% | 436,078 |
Delayed Quote Nasdaq Stockholm, May 28, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.24% | 575M | |
+16.34% | 79.03B | |
+8.65% | 8.78B | |
-16.33% | 4.83B | |
+51.22% | 4.65B | |
+2.18% | 3.89B | |
+20.51% | 2.34B | |
-26.79% | 2.18B | |
+15.12% | 2.11B | |
-36.56% | 2B |
- Stock Market
- Equities
- CALTX Stock